A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to JSKN003
Related studies linked through entity extraction aliases.
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Status
- RECRUITING
- Phase
- PHASE3
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Status
- RECRUITING
- Phase
- PHASE2
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
- Status
- COMPLETED
- Phase
- PHASE1